- Initiation of etrasimod Ph 2/3 program in Crohn's disease
(CD)
- Two additional Ph 2 etrasimod
development programs in eosinophilic esophagitis (EoE)
and alopecia areata (AA)
- First subject dosed in APD418 Ph 1 trial in
Decompensated Heart Failure (DHF)
- Expanded multi-program collaboration with Beacon
Discovery for immune and inflammatory targets (Project
Cabrillo)
- Formation of Arena Neuroscience, Inc.
focused on programs and platform to address microglial
neuroinflammation
- Arena to host conference call and webcast
tomorrow, January 7, at 9:00 AM ET
SAN DIEGO, Jan. 6, 2020 /PRNewswire/ --Arena
Pharmaceuticals, Inc. (Nasdaq: ARNA) will provide a corporate
update highlighting its strategic portfolio expansion on a
conference call tomorrow, January 7,
at 9:00 AM ET, and provide additional
detail at the 38th Annual J.P. Morgan Healthcare Conference taking
place January 13-16, 2020.
"Arena had a stellar year in 2019, starting with the closing of
the landmark ralinepag deal with United Therapeutics, and
successfully initiating multiple important Phase 2 and 3 trials
across our portfolio," stated Amit D.
Munshi, President and Chief Executive Officer of Arena.
"Building upon our success in 2019, we are preparing for future
growth with an expanded pipeline including two new indications for
etrasimod, an expanded collaboration with Beacon Discovery -
Project Cabrillo - focused on new immunology and inflammation
targets, and a new wholly owned subsidiary, Arena Neuroscience,
Inc., that will focus on programs and platform to address
microglial neuroinflammation. Arena is poised to build a bold,
vibrant, catalyst-rich company over the next decade as we focus on
the delivery of multiple important medicines."
Growth Drivers:
Clinical Pipeline
- Etrasimod in development for five gastrointestinal and
dermatologic indications targeting approximately $48B market opportunity
-
- Ongoing Ph 3 program in ulcerative colitis (UC)
- Ongoing Ph 2b data in atopic
dermatitis (AD)
- Initiation of Crohn's disease (CD) Ph 2/3 program
- New Ph 2b program in eosinophilic
esophagitis (EoE)
- New Ph 2 program in alopecia areata (AA)
- Olorinab
-
- Ongoing Ph 2b data in abdominal
pain associated with irritable bowel syndrome (IBS-C, IBS-D)
- APD418
-
- Ongoing Ph 1 trial in decompensated heart failure
(DHF)
Emerging Franchises
- Project Cabrillo with Beacon Discovery
-
- Relationship expansion with Beacon Discovery evaluating and
developing multiple immune and inflammatory targets
- Leverages Arena's historical GPCR expertise
- Arena Neuroscience, Inc. Platform
-
- Formation of new subsidiary focused on programs and platform to
address microglial neuroinflammation
Conference Call & Webcast Information
Arena will
host a conference call and live webcast with the investment
community tomorrow, Tuesday, January 7, 2020, at 9:00 AM
ET, to discuss our strategic plan and provide a corporate
update.
When: Tuesday, January 7, 2020, at 9:00 AM
ET
Dial-in: (877) 643-7155 (United
States) or (914) 495-8552 (International)
Conference ID: 8790636
Please join the conference call at least 10 minutes early to
register. You can access the live webcast under the investor
relations section of Arena's website
at: www.arenapharm.com. Shortly after the call, a replay of
the conference call will be archived under the events and
presentations section of Arena's website and available for 30
days thereafter.
About Arena Pharmaceuticals
Arena Pharmaceuticals is
uniquely positioned to develop best-in-disease medicines with
optimized efficacy and safety for patients globally. Our drive to
deliver a robust pipeline of novel, transformational medicines is
grounded in two decades of world class G-protein-coupled receptor
(GPCR) discovery research.
It is the breadth and depth of the portfolio, the prioritization
of drug development to meet unmet patient needs, the strong
financial health and the growing, bold-thinking world-class team
that gives Arena the ingredients and passion to build a
sustainable, vibrant next generation pharmaceutical company.
Forward-Looking Statements
Certain statements in this
press release are forward-looking statements that involve a number
of risks and uncertainties. These forward-looking statements may be
identified by introductory words such as "plan," "development,"
"targets," "focused on," "will," "preparing,"
"future," "poised to," "opportunity," "uniquely positioned
to," "drive to," or words of similar meaning, or by the fact that
they do not relate strictly to historical or current facts. Such
forward-looking statements include, without limitation, statements
about Arena's strategic plan, including as it relates to new and
ongoing clinical and preclinical programs, data readouts from such
programs, IND filings, the collaboration with Beacon Discovery, and
Arena Neuroscience and its focus, as well as Arena's position,
drive, assets, programs, licenses, and partnerships. For such
statements, Arena claims the protection of the Private Securities
Litigation Reform Act of 1995. Actual events or results may differ
materially from Arena's expectations. Factors that could cause
actual results to differ materially from the forward-looking
statements include, without limitation, the following: the timing
and outcome of research, development and regulatory review is
uncertain; clinical trials and other studies may not proceed at the
time or in the manner expected or at all; enrolling subjects in our
ongoing and intended clinical trials is competitive and
challenging; results of clinical trials and other studies are
subject to different interpretations and may not be predictive of
future results; nonclinical and clinical data are voluminous and
detailed, and regulatory agencies may interpret or weigh the
importance of data differently and reach different conclusions than
Arena or others, request additional information, have additional
recommendations or change their guidance or requirements before or
after approval; we expect to need additional funds to advance all
of our programs, and you and others may not agree with the manner
we allocate our resources; our drug candidates may not advance in
development or be approved for marketing; risks related to
unexpected or unfavorable new data; the risk that Arena's
partnership with Beacon may not result in the discovery or
development of compounds or medicines with immune or inflammatory
targets; risks related to relying on partners and other third
parties; risks related to developing and commercializing drugs;
Arena's and third parties' intellectual property rights; and
satisfactory resolution of litigation or other disagreements with
others. Additional factors that could cause actual results to
differ materially from those stated or implied by Arena's
forward-looking statements are disclosed in Arena's filings with
the Securities and Exchange Commission. These forward-looking
statements represent Arena's judgment as of the time of this
release. Arena disclaims any intent or obligation to update these
forward-looking statements, other than as may be required under
applicable law.
Corporate
Contact:
Kevin R. Lind
Arena Pharmaceuticals, Inc.
Executive Vice President and
Chief Financial
Officer
klind@arenapharm.com
858.210.3636
Arena Media Contact:
IR@arenapharm.com
858-453-7200
Logo -
https://mma.prnewswire.com/media/436843/Arena_Pharmaceuticals_Logo.jpg